Now Reading
Eli Lilly Sues Businesses Selling Knock-Off Versions Of Mounjaro

Eli Lilly Sues Businesses Selling Knock-Off Versions Of Mounjaro

Eli Lilly Sues Businesses Selling Knock Off Versions Of Mounjaro

Eli Lilly is all set to sue wellness centers, medical spas, and other compounding pharmacies in various states in the US that sell unapproved samples of its famous drug for diabetes, Mounjaro, which is also frequently used as an off-label drug for weight reduction.

In the lawsuits, Eli Lilly mentioned that

“filed in federal courts spanning several states, it accused four businesses of selling compounded versions of Mounjaro violating state laws because the drugs lack approval from the U.S. Food and Drug Administration.”

Lilly has also accused six other companies, which mostly include wellness centers and medical spas, due to multiple trademark violations, unfair competition, and false advertising by selling knockoffs under the name of Mounjaro.

The lawsuits intend to protect the patients, Lilly added in a statement. The company “cannot validate the safety or effectiveness of products claiming to contain Tirzepatide that are not our own branded product,” it said while referring to the active ingredient in Mounjaro.

Novo Nordisk also took similar kinds of legal actions against those companies that sold different versions of its popular weight reduction drug Wegovy previously this summer as the high demand resulted in keeping a short supply for a few of the doses.

See Also
Stainless Steel Lab Tables

“When companies circumvent the drug-approval process, safety and efficacy are, at best, unknown,” Lilly mentioned in the suit against the accused Better Life Pharmacy. “The danger is not merely theoretical, as manufacturing and distribution of unapproved new drugs of unknown quality has endangered or adversely impacted public health.”

Some of the experts from the company have been expecting the regulators in the United States to approve using Mounjaro for obesity from this year onwards.

Continue Reading:

View Comments (0)

Leave a Reply

Your email address will not be published.

Scroll To Top